Cardium Therapeutics (CRXM) Stock Price, News & Analysis

Company Overview

Cardium Therapeutics, Inc. is a specialty biopharmaceutical company headquartered in Houston, Texas, that develops and commercializes therapies in the fields of cardiovascular health and regenerative medicine. The company leverages proprietary biomaterial and controlled-release platform technologies to create product candidates designed to address chronic and hard-to-treat conditions.

In its cardiovascular segment, Cardium’s lead investigational therapy is RevaCor, an injectable, bioabsorbable collagen matrix impregnated with basic fibroblast growth factor. RevaCor is being studied for its potential to stimulate angiogenesis and improve myocardial perfusion in patients with refractory angina. The product utilizes a sustained-release mechanism intended to enhance delivery directly to the target tissue.

Cardium’s wound care efforts center on a full-thickness human dermal allograft marketed under the name DermaPure. Derived from donated human tissue and processed to preserve native extracellular matrix components, DermaPure is indicated for the treatment of chronic wounds such as diabetic foot ulcers and venous leg ulcers. The company expanded into this area through the acquisition of the Celleration wound care business in 2010, providing a commercial footprint in the U.S. market.

Founded in 1987, Cardium Therapeutics has focused on advancing platform technologies for therapeutic protein delivery and tissue regeneration. The company serves healthcare providers and patients across the United States and maintains research collaborations to support the clinical development of its product candidates.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRXM Stock Analysis - Frequently Asked Questions

How do I buy shares of Cardium Therapeutics?

Shares of CRXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardium Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Anavex Life Sciences (AVXL), Isoray (ISR), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO) and Intellipharmaceutics International (IPCIF).

Company Calendar

• Today: 10/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CRXM
• Previous Symbol: NYSE:CXM
• CIK: 772320
• Web: www.cardiumthx.com
• Phone: (858) 414-1477
• Fax: 858-436-1001
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A